Adverse Drug Event
Conditions
Brief summary
An open longitudinal observational study, non-randomized, which will include the adult population, attended by the SES, in which preference will be given to those patients under treatment with drugs that can produce relevant adverse effects. It is a naturalistic study in which no pharmacological or other type of intervention will be carried out, only the information recommended in the drug data sheet (pharmacogenetic biomarkers, relevant interactions and clinical contraindications) will be provided.
Interventions
None listed
Sponsors
Complejo Hospitalario Universitario de Badajoz
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
Patients with a recent diagnosis and who are to be or are being treated according to usual clinical practice, who meet the criteria to participate in the study, read the corresponding information sheet, sign informed consent and agree to participate, provided they meet the following inclusion criteria: General criteria for all patients: * Age ≥ 18 years. In case of minors, they may be included, under the following assumptions: * If the minor is under 12 years of age, participation will require the consent and signature of the informed consent document by both parents (or their guardian). * If the minor is between 12 and 16 years of age, a proxy informed consent form will be provided and signed by both parents (if both parents are present at the time of the interview) or only one of them (in which case one of the following two conditions must be stated: that the other parent is not present at the time of the interview but does not object to the participation of the minor in the study or that the signatory is the sole legal guardian of the minor). * Be registered or potentially/have been attended in the Extremadura Health Service. * Not have language or communication barrier or present disability being totally dependent on another person.
Exclusion criteria
* Failure to meet any of the inclusion criteria described above. * Refusal by the patient to be part of the cohort initially, or to continue to be part of the cohort during follow-up. * Manifest difficulty for follow-up.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the implementation of the Pharmacogenetics and Personalized Medicine Program MedeA in the Extremadura Health Service. | December 2024 | To analyze the implementation in the clinical routine of a pharmacogenetics and personalized medicine program in SES patients, evaluating the overall impact on the health system, and at the individual level, general modifications in the clinical response and its temporal evolution. |
Countries
Spain
Outcome results
None listed